Drug Approval | December 28, 2021
Torrent Pharma to launch molnupiravir under the brand name Molnutor in India
DCGI approved the drug based on the review of clinical data
DCGI approved the drug based on the review of clinical data
The company will market it under the brand name Molflu
The drug will be marketed under the brand name Molnaflu
The company has developed the API in house at its R&D center in Hyderabad
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The drug is being developed at lab scale for the first-line of treatment of Covid-19
Subscribe To Our Newsletter & Stay Updated
